{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-25-046076","form_type":"8-K","ticker":"IRIX","cik":"0001006045","company_name":"IRIDEX CORP","filed_at":"2025-03-27T23:59:59+00:00","discovered_at":"2026-05-14T18:03:02.673880+00:00","generated_at":"2026-05-24T03:34:03.614806+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Iridex posts Q4 2024 revenue $12.7M, achieves positive adjusted EBITDA; net loss narrows to $0.8M","bullets":["Q4 revenue $12.7M vs $12.5M YoY; adjusted EBITDA positive $0.4M vs ($2.0M) loss prior year.","Net loss improved to $0.8M ($0.05/share) from $3.0M ($0.18/share); operating expenses down 24% to $6.1M.","Cyclo G6 product family revenue $3.3M (+9% YoY); retina product revenue $7.3M (-3%).","Cash $2.4M at year-end; subsequent $10M strategic investment from Novel Innovations at $2.00/share.","Guidance: expects cash flow breakeven and positive adjusted EBITDA in 2025 on FY revenue consistent with 2024."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-25-046076","json":"https://secwatch.observer/filing/0000950170-25-046076.json","markdown":"https://secwatch.observer/filing/0000950170-25-046076.md","text":"https://secwatch.observer/filing/0000950170-25-046076.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1006045/000095017025046076/0000950170-25-046076-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1006045/000095017025046076/irix-20250327.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-24T03:34:03.614806+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}